4-(4-Aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

Catalog No. :
ACPKAQ785
CAS No. :
2376990-29-1
Molecular Formula :
C17H20ClN3O5
Molecular Weight :
381.82

IUPAC Name:4-(4-aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

4-(4-Aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$93.00Login to see priceIn stockInquiry
100mg98%$147.00Login to see priceIn stockIn stock
250mg98%$270.00Login to see priceIn stockIn stock
1g98%$710.00Login to see priceIn stockInquiry
5g98%$2021.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4-Aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
IUPAC Name4-(4-aminobutoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
MDL No.MFCD32705123
Molecular FormulaC17H20ClN3O5
Molecular Weight381.82
SMILESO=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3OCCCCN)=O.[H]Cl
InChI KeyVRXZGWPQXJYEPH-UHFFFAOYSA-N
SynonymThalidomide - linker 9 | 4-(4-Aminobutoxy)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione hydrochloride
CAS No.2376990-29-1
PubChem CID145874881

Safety Data

Pictogram
Health hazard
Signal Word
Danger
Hazard Statement(s)
H360
Precautionary Statement(s)
P201-P202-P280-P308+P313-P405-P501

Synthetic Route by SureRoute

1. ACPKAQ785 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPKAQ785 route product structure diagram
    ACPKAQ7852376990-29-1 In Stock
Inquiry

2. ACPKAQ785 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPKAQ785 route product structure diagram
    ACPKAQ7852376990-29-1 In Stock
Inquiry

Comments (0)